NCT03371849

PK and Safety Study of HCP1102, HGP0813 and HGP1408

A Randomized, Open Label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of HCP1102 in Comparison to HGP0813 and HGP1408 Administered in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: Male
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is a randomized, open label, single dose, two-way crossover clinical trial to investigate the pharmacokinetics and safety/tolerability of HCP1102 in comparison to HGP0813 and HGP1408 administered in healthy male volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	montelukast and levocetirizine FDC	HCP1102
DRUG	Singulair + xyzal	HGP0813 + HGP1408

Timeline

• Start date: 2017-07-19
• Primary completion: 2017-08-03
• Completion: 2017-08-03
• First posted: 2017-12-13
• Last updated: 2017-12-13

Locations

1 site across 1 country: South Korea